Thomas Olencki

10.8k citations
122 papers · 4.0k · 2 hit papers · h-index 30

Impact in

Papers in

Thomas Olencki

120 papers receiving 3.9k citations

Hit Papers

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial 2018 · 274 citations
2740+3+6Years since publication100200300400500

Peers

Thomas Olencki
Comparison fields: 5 of 108
  • Oncology 2.0k
  • Pulmonary and Respiratory Medicine 1.8k
  • Cancer Research 797
  • Immunology 886
  • Molecular Biology 1.6k
Replace Jens Atzpodien with:
Jens Atzpodien Germany
Salvador Martín‐Algarra Spain
Dimitrios Bafaloukos Greece
Heounjeong Go South Korea
Xavier Sagaert Belgium
Patricia Pautier France
Takeshi Hanagiri Japan
Massimo Barberis Italy
Kirsten B. Goldberg United States
Ranee Mehra United States
Thomas Olencki relative to Jens Atzpodien Germany Jens Atzpodien's profile →
Citations per field
00.5×5.2×
Jens Atzpodien · 1×
Citations per year

Countries citing papers authored by Thomas Olencki

Since Specialization
Citations

This map shows the geographic impact of Thomas Olencki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Olencki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Olencki more than expected).

Fields of papers citing papers by Thomas Olencki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Olencki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Olencki. The network helps show where Thomas Olencki may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Olencki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Olencki Line = papers co-authored together Thomas Olencki links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Hit paper breakdown →
2017507
2 2014352
3
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Hit paper breakdown →
2018274
4 2018267
5
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
1998194
6 2003126
7 2018121
8 2015117
9
A Global Review of Melanoma Follow-up Guidelines.
2013116
10 2011100
11 201697
12 199579
13 201978
14 201776
15 201775
16 200863
17 201658
18 200457
19 200354
20
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
199849

About Thomas Olencki

Thomas Olencki is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Cancer Research, having authored 122 papers that have together received 4.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (32 papers), Renal cell carcinoma treatment (31 papers), Immunotherapy and Immune Responses (18 papers), CAR-T cell therapy research (14 papers), Melanoma and MAPK Pathways (13 papers), Cancer Genomics and Diagnostics (13 papers), Renal and related cancers (11 papers) and Lung Cancer Research Studies (11 papers). The work is most often cited by research in Oncology (2.0k citations), Pulmonary and Respiratory Medicine (1.8k citations), Cancer Research (797 citations), Immunology (886 citations) and Molecular Biology (1.6k citations). Thomas Olencki has collaborated with scholars based in United States, Switzerland and Italy. Frequent co-authors include Ronald M. Bukowski, Toni K. Choueiri, Eric J. Small, Geoffrey I. Shapiro, Daniel J. George, Shaker R. Dakhil, M. Dror Michaelson, Ben L. Sanford, Joel Picus and Michael J. Morris. Their work appears in journals such as Journal of Clinical Oncology, Journal of Immunotherapy, Annals of Oncology, Investigational New Drugs and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact